Loading stock data…
TRDA
$6.37+0.11 (+1.76%)
Market OpenUpdated 3:37 PM EDT
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Entrada Therapeutics, Inc. in the Healthcare sector is trading at $6.37 with a market capitalization of $274M. Wall Street consensus targets $18.75 (4 analysts), implying a +194.3% move over the next 12 months. The stock is currently near its 52-week low of $4.93, remaining 32.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +194.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.37
Potential Downside
0%
Whystock Fair Value$6.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$18.75+194.3%
Range$10.00 – $25.00
Fundamentals
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$274.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.39%
Volume
Today's trading volume
120,120
Recent News
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping
Entrada’s stock drops as DMD drug’s efficacy falls short
At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota.
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys.
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6%
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?